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IMPACT OF DISEASE AND MOBILIZING AGENTS ON INITIAL AND RE-
MOBILIZATION FAILURE
DiPersio, J.F.1, Smith, A.2, Sempek, D.2, Baker, A.2, Jiang, S.3,
Vij, P.1, Cashen, A.1, Westervelt, P.1 1Washington University, St.
Louis, MO; 2Barnes-Jewish Hospital, St. Louis, MO; 3University of
British Columbia, Vancouver, BC, Canada.
Background: High-dose chemotherapy with autologous stem cell
transplantation (ASCT) is a common treatment strategy in lymphoma
and myeloma, but no standard approach for the mobilization of
peripheral hematologic stem and progenitor cells has been estab-
lished. Levels of circulating CD34 cells, a surrogate marker for
mobilization efﬁciency, vary widely between pts, and may be inﬂu-
enced by disease state, prior therapy, and/or mobilization regimen.
Methods: The Washington University (St. Louis, MO) transplanta-
tion database includes clinical parameters from 407 MM, 562 NHL,
and 164 HD pts who received an ASCT (1995-2006). A retrospective
analysis of this large (1133 pts) population was conducted to deter-
mine factors associated with mobilization efﬁciency. Mobilization
failure was deﬁned as collection of  2  10^6 CD34 cells/kg
within 5 apheresis days. Statistical analysis included ANOVA with
Scheffe Test to determine differences in mobilization between the
various mobilization regimens (G-CSF, G-CSF/chemotherapy, G-/
GM-CSF, G-CSF/AMD3100). Results: All pts were included in the
analysis; 87% received G-CSF alone as the initial mobilization regi-
men. Mobilization failure rates are summarized in Table 1. NHL and
HD pts had a 4-fold higher failure rate than MM pts. G-CSF/chemo
increased the median CD34 yield compared to G-CSF alone, al-
though no obvious impact on the failure rate was noted in this
relatively small group of pts. Remobilization was associated with high
failure rates inNHL (79.2%), HD (77.1%), andMM (73.3%). Pooled
collections were2 10^6 CD34/kg in 33.6%, 37.1%, and 36.7%
of failed mobilizers, resp. G-CSF mobilization failures remobilized
with G-CSF plus AMD3100 collected signiﬁcantly more CD34
cells than G-CSF-failures remobilized with either G-CSF, G/GM-
CSF or G-CSF/chemo (1-way ANOVA: F(3, 233)  27.878, F0.5(3,
233).05  2.643, p  .0001). The compared groups did not signiﬁ-
cantly differ in initial mobilization efﬁciency with G-CSF (as deter-
mined by ANOVA and Scheffe Test). Conclusions: The mobiliza-
tion failure rate is substantially higher in NHL and HD pts than MM
pts. Pts who fail initial mobilization are likely to fail a 2nd mobiliza-
tion, regardless of disease state. As the combination of chemotherapy
to G-CSF may not be sufﬁcient to reduce failure rates, alternative
mobilization strategies are needed to improve HSPC collection, par-
ticularly in NHL/HD pts and failed mobilizers.
First mobilization failures ( 210^6 CD34/kg)
Mobilization
regimen N Failures
Median
yield
(x10^6)
Median
yield
(x10^6)
NHL G-CSF 471 26.5% 2.89 2.76-3.04
G-CSF/Chemo 35 22.9% 4.68 2.8-8.53
All* 564 28.7%
HD G-CSF 130 26.2% 3.01 2.75-3.37
G-CSF/Chemo 12 16.7% 5.38 2.35-9.52
All* 165 24.8%
MM G-CSF 386 6.5% 4.62 4.16-4.98
G-CSF/Chemo 17 5.9% 8.52 4.46-16.3
All* 409 6.6%
*Incl. pts mobilized w. alternative regimens
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AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT USING
BUSULFAN, ETOPOSIDE, HIGH DOSE ARA-C, AND G-CSF PRIMING AS
CONDITIONING REGIMEN IN PATIENTS WITH ACUTE MYELOID LEU-
KEMIA IN FIRST COMPLETE REMISSION
Moscardo´, F.1, Dı´az Mediavilla, J.2, de la Rubia, J.1, Ferna´ndez, P.3,
Rayo´n, C.4, Can˜igral, G.5, Arias, J.6, Palomera, L.7, Bello, J.L.8,
Alcala´, A.9, Sayas, M.J.10, Burgaleta, C.11, Mateos, M.12,
Amador, L.13, Pe´rez, M.14, Ferna´ndez, R.15, Garcı´a, J.16,
Martı´n, M.V.17, Roma´n, A.18, Queiza´n, J.A.19, Ferna´ndez, J.20,
Sanz, M.A.1, from the PETHEMA Cooperative Study Group. 1Hospital
Universitario La Fe, Valencia, Spain; 2Hospital Clı´nico San Carlos,
Madrid, Spain; 3Hospital General de Alicante, Alicante, Spain; 4Hos-
pital Central de Asturias, Oviedo, Spain; 5Hospital General de Castello´n,
Castello´n, Spain; 6Hospital Xeral Lugo, Lugo, Spain; 7Hospital Clı´nico
Universitario Lozano Blesa, Zaragoza, Spain; 8Hospital Clı´nico Uni-
versitario Santiago de Compostela, Santiago de Compostela, A Corun˜a,
Spain; 9Hospital General de Jaen, Jaen, Spain; 10Hospital Dr. Peset,
Valencia, Spain; 11Hospital Universitario Prı´ncipe de Asturias, Alcala´ de
Henares, Madrid, Spain; 12Hospital Clı´nico de Salamanca, Salamanca,
Spain; 13Complejo Hospitalario Montecelo-Pontevedra, Pontevedra,
Spain; 14Hospital Virgen de La Concha, Zamora, Spain; 15Hospital
Insular de Las Palmas, Las Palmas, Spain; 16Hospital Ramo´n y Cajal,
Madrid, Spain; 17Hospital Universitario Puerta del Mar, Ca´diz, Spain;
18Hospital Fundacio´n Jime´nez Dı´az, Madrid, Spain; 19Hospital General
de Segovia, Segovia, Spain; 20Hospital Universitario de Valladolid,
Valladolid, Spain.
Introduction: Conditioning regimens for autologous stem cell
transplantation (ASCT) in patients with acute myeloid leukemia
(AML) using more speciﬁc drugs for myeloid malignancies, such as
high-dose Ara-C (HD/Ara-C) and etoposide, have been increas-
ingly proposed as an alternative the classic BUCY schedule. Ob-
jectives: To analize safety and efﬁcacy of a conditioning regimen
combining busulfan, etoposide, HD/Ara-C, and G-CSF priming
for patients with AML in ﬁrst complete remission (CR1) under-
going ASCT. Patients: 147 patients with AML in CR1 after
induction and consolidation therapy with idarubicin or daunoru-
bicin and Ara-C following a ‘37’ schedule (PETHEMA LMA99
trial) underwent ASCT. They were 65 male and 82 female with a
median age 46 years. The median WBC and platelet counts at
presentation were 2  109/L (range, 0.04-193) and 59  109/L
(range, 7-578), respectively. According to the MRC criteria, 125
patients with available karyotype (85%) were classiﬁed as follows:
24 patients (19%) with standard risk, 87 patients (70%) with
intermediate risk, and 14 patients (11%) with high risk. Condi-
tioning regimen consisted of busulfan 1 mg/kg/6 hours on days -8
to -5, etoposide 20 mg/kg/day on days -4 and -3, Ara-C 3 g/m2/12
hours on days -3 and -2, and G-CSF 10 g/kg/day on days -9 to -2.
Results: Median time from diagnosis to ASCT was 6 months.
Median time to neutrophil count recovery above 0.5  109/L was
12 days (range, 5-90) and days of hospital stay was 29 days (range,
11-94). Thirty-two percent of patients had bacteremia, 9.5% doc-
umented infection without bacteremia , and 21% clinically docu-
mented infection without microbiological documentation. The
most relevant extrahematological toxicity was gastrointestinal tox-
icity grade 3 (36%). Event-free survival (EFS) at 4 years was
53%. Cytogenetics was the only variable associated to EFS: 62%
for standard-risk group, 52% for intermediate-risk group, and 24%
for high-risk group (P  0.0066). Five patients died due to ASCT
(transplant-related mortality, 3.4%). Four of them died before day
100 mainly due to infections, while the remaining patient died of
pulmonary thromboembolism 31 months after ASCT. Conclu-
sions: The conditioning regimen combining busulfan, etoposide,
HD/Ara-C, and G-CSF priming shows a high antileukemic efﬁ-
cacy in patients with AML in CR1. This regimen shows a moderate
toxicity proﬁle and low transplant-related mortality. Citogenetics
was the only prognostic factor identiﬁed for EFS.
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ARSENIC TRIOXIDE WITH ASCORBIC ACID AND HIGH-DOSE MELPHA-
LAN FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION FOR MULTIPLE MYELOMA
Qazilbash, M.H.1, Jindani, S.2, Gul, Z.2, Saliba, R.1, Hosing, C.1,
Mendoza, F.1, Qureshi, S.P.1, Weber, D.M.1, Wang, M.1, Flosser, T.1,
Couriel, D.P.1, Kebriaei, P.1, Popat, U.1, Alousi, A.M.1, De Lima, M.1,
Champlin, R.E.1, Giralt, S.A.1 1University of Texas - MD Anderson
Cancer Center, Houston, TX; 2Wayne State University/Detroit Medical
Center, Detroit, MI.
Backround: Arsenic trioxide (ATO) has been shown to be syner-
gistic with melphalan both in vitro and in vivo.We conducted a phase
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I/II trial to determine the safety and efﬁcacy of a combination of
arsenic trioxide, melphalan and ascorbic acid (AA) as preparative
regimen in patients undergoing high-dose therapy (HDT) and autol-
ogous hematopoietic progenitor cell transplantation for multiple my-
eloma (MM). We also assessed the impact ATO levels on melphalan
pharmacokinetics (PK), engraftment and toxicity.
Methods: Forty-eight patients with secretory myeloma (23 females,
25 males; median age: 54, range: 35-70) were treated between 4/04
and 8/05. All patient received melphalan 100 mg/m2 IV on days -4
and -3 and AA 1000 mg/day IV on days -9 to -3. Patients were
randomized to 3 arms; no ATO (arm 1), ATO 0.15 mg/kg IV on days
-9 to -3 (arm 2) and ATO 0.25 mg/kg IV on days -9 to -3 (arm 3).
Twelve patients had a prior autograft. Median CD34 cells dose in-
fused was 4.5  106/kg (range 2.3 -10.9).
Results: Patients in all 3 arms were evenly matched.With a median
F/U of 17 months (range 6-29) post autograft, no dose-limiting
toxicity or non-relapse mortality was seen. Toxicity was limited to
grade I or II nausea, vomiting and diarrhea and was similar in all 3
arms. Melphalan PK was not altered by ATO pretreatment. Median
time to neutrophil engraftment (ANC 500/ dl) was 9 days, with no
engraftment failures or delays in the ATO arms. CR rate for the entire
group was 23%, and overall response rate (ORRCR  PR) was
75%. Progression-free survival (PFS) and overall survival (OS) after
17-month F/U were 68% and 82%, respectively. There was no
signiﬁcant difference in CR, ORR, PFS or OS between the 3 arms (p
 0.9, 0.9, 0.5 and 0.6, respectively). A prior autologous transplant (p
 0.02) and abnormal cytogenetics at transplant (p  0.04) were
associated with a signiﬁcantly shorter remission.
Conclusions: ATO  melphalan  ascorbic acid is a safe,
effective and well tolerated preparative regimen for patients with
multiple myeloma undergoing an autotransplant. A prior autograft
and abnormal cytogenetics are associated with worse outcome.
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AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ELDERLY PA-
TIENTS WITH MULTIPLE MYELOMA
Qazilbash, M.H.1, Gul, Z.2, Jindani, S.2, Saliba, R.1, Hosing, C.1,
Mendoza, F.1, Qureshi, S.P.1, Weber, D.M.1, Wang, M.1, Flosser, T.1,
Couriel, D.P.1, De Lima, M.1, Kebriaei, P.1, Popat, U.1, Alousi, A.M.1,
Champlin, R.E.1, Giralt, S.A.1 1UT-MD Anderson Cancer Center,
Houston, TX; 2Wayne State University/ Detroit Medical Center (Grace
Program), Detroit, MI.
Background: Several trials have shown that autologous stem cell
transplantation is superior to conventional therapy in terms of
complete response (CR) rate, event-free survival (EFS) and overall
survival (OS). This treatment, however, is generally limited to
patients younger than 65 due to concerns about excessive toxicity
and treatment-related mortality (TRM) in older patients. Previous
reports have shown that age alone should not exclude patients from
high-dose therapy, as long as they fulﬁll other eligibility criteria. In
this report we analyzed the safety and efﬁcacy of high-dose che-
motherapy (HDT) and autologous transplant in patients with MM
who were  70 years at the time of autotransplant.
Methods: Twenty-six patients (16 males, 10 females) with a
median age of 72 (range 70-79) underwent HDT and an autograft
between July 1999 and October 2005. The preparative regimen
was melphalan 200 mg/m2 in 19 patients (73%), melphalan 180
mg/m2 in 6 and melphalan140 mg/m2 in 1 patient. Of the 26
patients, 12 were receiving ﬁrst remission consolidation, 7 had
primary refractory disease and 7 had relapsed disease. Clonal cy-
togenetic abnormalities were present in 5 patients (19%).
Results: Twenty-two of the 26 patients were alive after a median
follow up of 25 months (range 8-74). Responses (complete 
partial response) were seen in 20 patients (77%), ﬁve (19%) of
which were complete responses. Median PFS was 24 months and
median OS has not been reached yet. 100-day TRM was 0%.
Median times to absolute neutrophil count of 0.5  109/l and
platelets 20  109/l were 10 and 10 days, respectively. Three-
year PFS and OS were 39% and 65%, respectively. A serum
albumin 3.5 g/dl (p0.02), abnormal cytogenetics at transplant
(p0.05) and 2 prior chemotherapy regimens (p0.02) were
associated with a shorter PFS. Patients transplanted with relapsed
disease had a shorter OS (p0.0004). ISS stage, 2 microglobulin
level, lactic dehydrogenase (LDH) level, abnormal cytogenetics,
CCI or HCT-CI at the time of transplant did not emerge as
signiﬁcant predictors of PFS or OS in this group of patients.
Conclusions: HDT and autologous transplant is safe and feasi-
ble in selected patients70 years of age. Patients transplanted with
relapsed disease had a shorter OS.
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TOTAL MARROW IRRADIATION (TMI) USING HELICAL TOMOTHERAPY:
DOSIMETRIC ANALYSIS DEMONSTRATES REDUCED ORGAN DOSES
WHICH CORRELATE WITH REDUCTION IN ACUTE TOXICITIES AND
PREDICT FOR ESCALATION OF DOSE TO TARGET MARROW BEYOND
THAT ACHIEVABLE BY STANDARD TBI
Wong, J.Y.C.1, Liu, A.1, Schultheiss, T.1, Parker, P.1, Krishnan, A.1,
Sahebi, F.1, Karanes, C.1, Spielberger, R.1, Rosenthal, J.1, Forman, S.1,
Somlo, G.1 1City of Hope Cancer Center, Duarte, CA.
TBI dose escalation has been difﬁcult due to associated organ
toxicities. We recently demonstrated the feasibility of using Tomo-
therapy (an image guided IMRT delivery system) to deliver a more
targeted dose of TBI to sites of greatest tumor burden (bone/marrow)
with reduced dose to normal organs in a patient with multiple my-
eloma. This study provides a dosimetric analysis of target bone/
marrow and normal organ doses from the ﬁrst 13 patients treated, and
details of set-up and delivery using this novel system.
Twelve patients with multiple myeloma (MM) were treated with
Mel (200 mg/m2) followed 6 weeks later by TMI as part of a tandem
autologous transplant Phase I/II trial. Total TMI doses were 10 Gy (3
patients), 12 Gy (4 patients), 14 Gy (3 patients) and 16 Gy (2 patients)
delivered 2 Gy QD or BID over 5 days. One patient with AML was
treated with TMITLI to 12 Gy (1.5 Gy BID)  concomitant
Flu/Mel on a separate trial. Treatment time was 50 minutes, jaw size
2.5 cm, and pitch 0.45. Patients were treated supine with full body
immobilization. Whole body CT imaging was performed by the
Tomotherapy unit prior to each fraction to provide 3D alignment of
patient anatomy to the intended target regions.
Median organ doses ranged from 15-65% that of the target bone/
marrow dose. The degree of organ sparing was similar for all patients
despite differences in thickness and habitus. Of the 84 TMI treatment
sessions delivered, only one was temporarily interrupted due to nausea
and vomiting. In the immediate post-TMI period, all MM patients
experienced grade 1-2 nausea, with half experiencing no vomiting.
Erythema, diarrhea, and mucositis were infrequent and grade 1-2.
The AML patient experienced grade 2 nausea, grade 1 vomiting and
grade 3 mucositis. This compares favorably to acute symptoms asso-
ciated with large ﬁeld hemibody RT or standard TBI.
This study conﬁrms the feasibility of using Tomotherapy to deliver
TMI. Dosimetric studies demonstrated reduced organ doses and
predicted for reduced toxicities. Clinical results conﬁrmed these pre-
dictions. The techniques used can be adapted bymost centers with the
technology. This study predicts for the ability to dose escalate to a
level where normal organs receive comparable standard TBI doses
with target regions receiving a signiﬁcantly higher dose than achiev-
able with TBI, offering the potential for improved outcomes in pa-
tients with hematologic malignancies.
GRAFT PROCESSING
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EX-VIVO EXPANSION (EvE) OF PREVIOUSLY CRYOPRESERVED CORD
BLOOD (CB) INTO NATURAL KILLER (NK) CELLS WITH ENHANCED
AML AND NEUROBLASTOMA CYTOTOXICITY: POTENTIAL ROLE OF CB
NK CELLS IN ADOPTIVE CELLULAR IMMUNOTHERAPY (ACI)
Ayello, J.1, Satwani, P.1, van de Ven, C.1, Shereck, E.1, Roman, E.1,
Wapner, R.J.2, Cairo, M.S.1,3,4
1
Department of Pediatrics; 2Obstetrics/
Gynecology; 3Medicine; 4Pathology, New York-Presbyterian, Columbia
University.
CD56 NK subsets exhibit differential NK receptors (NKR)
such as cytotoxicity proﬁles including killer-Ig-like receptors
(KIR), C-lectin (NKG2) and natural cytotoxicity receptors (NCR)
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